Our findings demonstrate the clinical relevance of the PIEZO1 ion channel in breast cancer and highlight the importance of PIEZO1 expression on patient survival and its potential as a prognostic biomarker in HR-negative breast cancer patients. This evidence concerns the gene PIEZO1 and breast cancer.